Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies

    loading  Checking for direct PDF access through Ovid

Abstract

It is now widely accepted that current standard therapy does not lead to cure for the majority of patients with B-cell malignancies. In the search for novel treatment modalities and with the discovery of tumor-antigen-derived peptides recognized by T cells in the context of major histocompatibility complex class I and II molecules, active and passive immunotherapy has moved to center stage once again. Whereas most lymphoma research in this area has focused on vaccination strategies using the tumor-specific idiotype as a target antigen, this review focuses on the potential of a new strategy of adoptive transfer of antigen-specific T- for B-cell malignancies. Murine in vivo models and preclinical experiments suggest that we are now ready to enter the clinical arena to evaluate whether adoptive transfer of autologous or allogeneic antigen-specific T cells is a feasible and efficacious therapy approach for the treatment of B-cell malignancies. Potential obstacles to this strategy are also discussed.

Related Topics

    loading  Loading Related Articles